Browse

Recalcitrant Atopic Dermatitis Treated with Omalizumab

Cited 23 time in Web of Science Cited 29 time in Scopus
Authors
Park, Se-Young; Choi, Mi-Ra; Na, Jung-Im; Youn, Sang-Woong; Huh, Chang-Hun; Park, Kyoung-Chan
Issue Date
2010-08
Publisher
KOREAN DERMATOLOGICAL ASSOC
Citation
ANNALS OF DERMATOLOGY; Vol.22, no.3; 349-352
Keywords
Atopic dermatitisBiologiesOmalizumab
Abstract
Atopic dermatitis (AD) is a chronic cutaneous inflammatory disease. Various categories of therapeutic medications are used for treating AD. Omalizumab is a monoclonal anti-IgE antibody that binds to IgE molecules at the high-affinity receptor (Fc epsilon RI) binding site. Therefore, omalizumab can be used as a potential new systemic treatment agent for recalcitrant AD patients with elevated IgE levels. A 34-year-old man had been treated for AD with several topical and oral agents. However, he was refractory to these therapies and his serum IgE levels were very high. We treated him with omalizumab. After 8 months of the treatment, his symptoms were notably improved and the SCORAD index was decreased. Thus, we report on the first case of recalcitrant AD that was successfully treated with omalizumab in Korea.
ISSN
1013-9087
Language
English
URI
http://hdl.handle.net/10371/78334
DOI
https://doi.org/10.5021/ad.2010.22.3.349
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dermatology (피부과학전공)Journal Papers (저널논문_피부과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse